Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

21.35 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 21.35
Bid (Size) 20.18 (1)
Ask (Size) 22.59 (1)
Prev. Close 21.35
Today's Range 21.35 - 21.35
52wk Range 18.98 - 36.95
Shares Outstanding 80,300,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap: Myriad Genetics Q1 Earnings
Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Myriad Genetics's Earnings: A Preview
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad... 
Via Benzinga

Performance

YTD
-23.78%
-23.78%
1 Month
-2.24%
-2.24%
3 Month
-16.80%
-16.80%
6 Month
-22.97%
-22.97%
1 Year
-24.82%
-24.82%

More News

Read More
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
Via Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
Via Benzinga
Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For November 2, 2021
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Via Benzinga
What's Up With Myriad Genetics Shares Trading Higher Tuesday?
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Via Benzinga
Exposures COVID-19
Myriad Genetics Insider Sold Over $None In Company Stock
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
4 Stocks Insiders Are Buying
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Via Benzinga
75 Biggest Movers From Yesterday
Via Benzinga
Myriad Genetics, inc (MYGN) Q2 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
48 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recap: Myriad Genetics Q3 Earnings
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Via Benzinga
Earnings Scheduled For August 3, 2021
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
Via Benzinga
70 Biggest Movers From Yesterday
Via Benzinga
Earnings Scheduled For May 3, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.